MSLE Satellos Bioscience Inc.
$9.75▼ -2.99%
Healthcare
Other
After hours
$9.75▲ +0.00%
Sep 11, 7:30 PM ET
Volume 33.4K
Avg Volume (10D) 35.0K
Key Metrics & Fundamentals
Market Cap
$206.86M
P/E Ratio
–
Div Yield
–%
52W Range
5.30 - 13.40
% vs 50 MA
3.46%
% vs 200 MA
18.92%
RSI-14
54.2
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.14
Free Cash Flow
-$8.03M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$12.08M
COGS
–
Operating Exp
$12.17M
Operating Income
-$12.17M
EBIT
-$12.17M
Pretax Income
-$11.67M
Net Income
-$11.72M
EPS (Diluted)
-0.56
Price & Volume History
Loading chart…
Recent News
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
GlobeNewswire · Sep 9, 2026 11:00 AM
Satellos to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 1, 2026 11:00 AM
LifeSci Capital Initiates Satellos Bioscience at Outperform
MT Newswires · Aug 25, 2026 11:27 AM
Satellos Bioscience: Q2 Earnings Snapshot
Associated Press · Aug 13, 2026 9:16 PM
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
GlobeNewswire · Aug 13, 2026 9:02 PM
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
MarketBeat · Jul 10, 2026 7:02 PM
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Benzinga · Jul 8, 2026 1:34 PM
Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients
MT Newswires · Jul 8, 2026 12:29 PM
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
GlobeNewswire · Jul 8, 2026 10:30 AM
Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation
MT Newswires · Jun 29, 2026 4:52 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See MSLE's money flow as a full page
Social Sentiment
No Reddit posts found for MSLE.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.